As industries undergo rapid transformation, emerging technologies are driving significant disruption across key sectors, enabling smarter decisions and fostering sustainable growth. From AI to advanced materials, Frost & Sullivan’s 15th Edition of the Top 50 Technologies provides critical insights to empower organizations in making strategic build, buy, or borrow decisions.

Is your organization equipped to leverage these technologies and stay competitive?

The 43rd JP Morgan Healthcare Conference, held from January 13–16, 2025, in San Francisco, brought together a vibrant ecosystem of global pharma stakeholders, innovative startups, emerging biotech companies, and investors.

This premier healthcare event showcased key themes such as AI in drug discovery, gene editing, personalized care, industry funding, and emerging trends in telehealth and mHealth, offering a platform for diverse stakeholders to present their capabilities and forge partnerships.

In an era where healthcare is increasingly shifting from one-size-fits-all solutions to personalized, predictive, and preventive care, global pharmaceutical companies face an urgent need to adapt.

Personalized Healthcare (PHC) is at the heart of this transformation, with its promise of tailored treatments and patient-centric solutions. However, the journey to adopting PHC at scale involves navigating a complex ecosystem, building sustainable business models, and fostering strategic vendor collaborations.

The healthcare and life sciences industries are witnessing unparalleled growth, fueled by technological advancements, shifting patient expectations, and evolving industry dynamics.

With the global healthcare industry expected to surpass $3 trillion by 2025, there has never been a better time for companies to leverage emerging growth opportunities. Frost & Sullivan’s latest analysis identifies the top 10 growth opportunities (GOs) that promise to reshape the healthcare landscape.

The landscape of immune-oncology (I-O) is rapidly evolving, driven by groundbreaking innovations in cell therapies and immune checkpoint inhibitors (ICIs). As the leading class of I-O agents, ICIs continue to be a foundational treatment for various cancers, while emerging therapies like Chimeric Antigen Receptor T (CAR-T) and Natural Killer (NK) cells are offering new avenues for targeted and more effective treatments.

The industry is witnessing an unprecedented surge in transactions, with companies focusing on expanding and diversifying their I-O portfolios to include promising candidates across clinical stages.